{"id":"aldoxorubicin-hcl","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL2107818","moleculeType":"Small molecule","molecularWeight":"750.76"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The selective release of doxorubicin from Aldoxorubicin HCl occurs in the acidic lysosomes of cancer cells, leading to DNA damage and apoptosis. This mechanism aims to reduce systemic toxicity associated with conventional doxorubicin administration.","oneSentence":"Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:26.619Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"}]},"trialDetails":[{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT03647423","phase":"PHASE1, PHASE2","title":"QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08-31","conditions":"Chordoma, Unresectable Malignant Neoplasm","enrollment":""},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03554109","phase":"PHASE2","title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-09","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":""},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT03586869","phase":"PHASE1, PHASE2","title":"QUILT-3.080: NANT Pancreatic Cancer Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-07-17","conditions":"Pancreatic Cancer","enrollment":3},{"nctId":"NCT03387085","phase":"PHASE1, PHASE2","title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-03-19","conditions":"Triple Negative Breast Cancer","enrollment":9},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT03387098","phase":"PHASE1, PHASE2","title":"QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-12-28","conditions":"Pancreatic Cancer","enrollment":4},{"nctId":"NCT01673438","phase":"PHASE1","title":"Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2012-07","conditions":"Advanced Solid Tumor","enrollment":15},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Aldoxorubicin HCl","genericName":"Aldoxorubicin HCl","companyName":"ImmunityBio, Inc.","companyId":"immunitybio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects. Used for Solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}